Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Patients with myeloproliferative neoplasms (MPNs), including essential thrombocythemia, polycythemia vera, and myelofibrosis, are at increased risk of cardiovascular disease and complications. The most recognized cardiovascular complications among patients with MPN are arterial and venous thrombotic events. However, mounting evidence suggest that nonthrombotic cardiovascular complications, including heart failure and pulmonary hypertension, are also common and are associated with adverse outcomes and overall prognosis. Therefore, it is important that hematologists become aware of such complications and are able to identify them as they arise. Additionally, cardiovascular disease treatment, including antithrombotic therapy and guideline-directed medical therapy for heart failure, may impact MPN-specific outcomes. Therefore, we review current literature of cardiovascular disease and complications among patients with MPNs and their impact on patient outcomes and prognosis.